L'Asparaginase and methotrexate combinations: Clashes of empiric success and laboratory models?

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 587-588

  Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; EMPIRICAL RESEARCH; ERWINIA; ERWINIA ASPARAGINASE; ESCHERICHIA COLI; HUMAN; MULTIVARIATE ANALYSIS; NOTE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; DRUG SYNERGISM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHOTREXATE;

EID: 34548401622     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181483e1b     Document Type: Note

References (14)

1. Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia. A Children's Oncology Group study. J Pediatr Hematol Oncol. 2007;29:627-632.
2. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia. 2000;14:1570-1576.
3. Harris MB, Shuster JJ, Pullen J, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2840-2847.
4. Mahoney DH, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246-254.
5. Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 2000;18:1285-1294.
6. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2803-2811.
7. Nachman JB, Sather JN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
8. Capizzi RL, Summers WP, Bertino JR. L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y. Ann N Y Acad Sci. 1971;186:302-311.
9. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep. 1981;65(suppl 4):115-121.
10. Lobel JS, O'Brien RT, McIntosh S, et al. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer. 1979;43:1089-1094.
11. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14:2247-2256.
12. Kamen BA, Winick N, Holcenberg J. Oral vs IV MTX: another opinion. J Clin Oncol. 1998;16:2283-2284.
13. Sur P, fernandes DJ, Kute TE, et al. L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res. 1987;47:1313-1318.
14. Kamen BA. High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how? J Pediatr Hematol Oncol. 2004;26:333-336.